| Date | Title | Description |
| 20.12.2023 | Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia raises $55M; Lassen fuels for fibro-inflammatory mission | We've launched a new Fierce Biotech Fundraising Tracker for 2023 to track all the venture capital flowing into the industry.
While biotech VC investments in 2022 failed to live up to 2021's banner year, the second half still saw a steady st... |
| 24.05.2023 | USA-based Quanta Therapeutics raises USD 50.7 million in Series D | California, USA-based biopharmaceutical company pioneering targeted therapies to treat RAS-driven cancers, Quanta Therapeutics, raises USD 50.7 million in Series D financing. The round took place on May 22, 2023. Avidity Partners led the fi... |
| 23.05.2023 | Quanta Therapeutics Raises Over $50M in Series D Financing | Quanta Therapeutics, a San Francisco, CA-based biopharmaceutical company, raised over $50M in Series D funding.
The round, which brought the total amount to $142M, was led by Avidity Partners and was supported by existing investors includin... |
| 22.05.2023 | Quanta Therapeutics Raises Over $50 Million in Series D Financing to Advance its Pipeline of KRAS Inhibitors | - |
| 22.05.2023 | Quanta Therapeutics Raises Over $50 Million in Series D Financing |
SOUTH SAN FRANCISCO, CA, Quanta Therapeutics announced a $50.7 million Series D financing led by Avidity Partners.
>> Click here for more funding data on Quanta Therapeutics
>> To export Quanta Therapeutics funding data to P... |
| 22.05.2023 | Quanta Therapeutics Raises Over $50 Million in Series D Financing to Advance its Pipeline of KRAS Inhibitors | - |
| 22.05.2023 | Quanta Therapeutics Raises Over $50 Million in Series D Financing to Advance its Pipeline of KRAS Inhibitors | /EIN News/ -- – Funds will support advancement of two KRAS inhibitor programs into the clinic in 2024 –
– Financing led by Avidity Partners, with participation from syndicate of existing investors –
RADNOR, Pa. & SOUTH SAN FRANCISCO, Ca... |
| 26.10.2021 | Quanta Therapeutics Announces Oversubscribed $60 Million Series C Financing to Advance Novel RAS-targeting Programs | Series C Financing Led by Surveyor Capital (a Citadel company) and Vida Ventures
Differentiated mechanisms target RAS active conformation across all mutant forms, with potential to circumvent resistance mechanisms experienced with first gen... |
| 26.10.2021 | Quanta Therapeutics Announces Oversubscribed $60 Million Series C Financing to Advance Novel RAS-targeting Programs | Series C Financing Led by Surveyor Capital (a Citadel company) and Vida Ventures
Differentiated mechanisms target RAS active conformation across all mutant forms, with potential to circumvent resistance mechanisms experienced with first gen... |
| - | Quanta Therapeutics | “Quanta Therapeutics is pioneering allosteric modulation to directly restore conformational control of active RAS signaling at the cell membrane to inhibit the full scope of RAS-driven cancer types.” |
